Skip to main content
Top

Biotherapy

Issue 2/1997

Content (9 Articles)

Augumentation of splenic antitumor immunity by local immunotherapy in gastric cancer patients

Taro Wakasugi, Tsutomu Takeda, Takushi Monden, Yoshihiro Katsumoto, Isao Sakita, Hirohito Nagaoka, Mutsumi Fukunaga, Naohiro Tomita, Tetsuro Kobayashi, Hitoshi Shiozaki, Takashi Shimano, Morito Monden

Treatment of head and neck cancers with BRMs

Tomoyuki Yoshida, Tetsuro Saeki, Yumiko Aoyama, Tadao Okudaira, Takuya Okada, Sotaro Funasaka

Modulation of cisPlatin cytotoxicity by interleukin-1α and resident tumor macrophages

Paul G. Braunschweiger, Vathsala S. Basrur, Dayna Cameron, Laura Sharpe, Octavio Santos, James P. Perras, Bernd-Uwe Sevin, Arnold M. Markoe

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine